Evidence mapPaperPMID 30201894Full record

ArticleToxics2018

The NOAEL Metformin Dose Is Ineffective against Metabolic Disruption Induced by Chronic Cadmium Exposure in Wistar Rats.

Victor Enrique Sarmiento-Ortega, Eduardo Brambila, José Ángel Flores-Hernández, Alfonso Díaz, Ulises Peña-Rosas, Diana Moroni-González, Violeta Aburto-Luna, Samuel Treviño

Open access · goldAbstract read
In one paragraph

Article in Toxics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Victor Enrique Sarmiento-OrtegaLaboratory of Chemical-Clinical Investigations, Department of Clinical Chemistry, Faculty of Chemistry Science, University Autonomous of Puebla, 14 South. CQ1, University City, Puebla C.P. 72560, Mexico. qfb_veso111@hotmail.com.
Eduardo BrambilaLaboratory of Chemical-Clinical Investigations, Department of Clinical Chemistry, Faculty of Chemistry Science, University Autonomous of Puebla, 14 South. CQ1, University City, Puebla C.P. 72560, Mexico. eduardobrambila1@yahoo.com.mx.
José Ángel Flores-HernándezLaboratory of Chemical-Clinical Investigations, Department of Clinical Chemistry, Faculty of Chemistry Science, University Autonomous of Puebla, 14 South. CQ1, University City, Puebla C.P. 72560, Mexico. quimicoangel32@hotmail.com.
Alfonso DíazDepartment of Pharmacy, Faculty of Chemistry Science, University Autonomous of Puebla, 14 South. CQ1, University City, Puebla C.P. 72560, Mexico. dan_alf2005@yahoo.com.mx.
Ulises Peña-RosasDepartment of Analytic Chemistry, Faculty of Chemistry Science, University Autonomous of Puebla, 14 South. CQ1, University City, Puebla C.P. 72560, Mexico. quim_perua@hotmail.com.
Diana Moroni-GonzálezLaboratory of Chemical-Clinical Investigations, Department of Clinical Chemistry, Faculty of Chemistry Science, University Autonomous of Puebla, 14 South. CQ1, University City, Puebla C.P. 72560, Mexico. d.moroni_25@hotmail.com.
Violeta Aburto-LunaLaboratory of Chemical-Clinical Investigations, Department of Clinical Chemistry, Faculty of Chemistry Science, University Autonomous of Puebla, 14 South. CQ1, University City, Puebla C.P. 72560, Mexico. val_140485@hotmail.com.
Samuel TreviñoLaboratory of Chemical-Clinical Investigations, Department of Clinical Chemistry, Faculty of Chemistry Science, University Autonomous of Puebla, 14 South. CQ1, University City, Puebla C.P. 72560, Mexico. samuel_trevino@hotmail.com.ORCID 0000-0001-5679-1671
Benemérita Universidad Autónoma de Puebla · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous studies have proposed that cadmium (Cd) is a metabolic disruptor, which is associated with insulin resistance, metabolic syndrome, and diabetes. This metal is not considered by international agencies for the study of metabolic diseases. In this study, we investigate the effect of metformin on Cd-exposed Wistar rats at a lowest-observed-adverse-effect level (LOAEL) dose (32.5 ppm) in drinking water. Metabolic complications in the rats exposed to Cd were dysglycemia, insulin resistance, dyslipidemia, dyslipoproteinemia, and imbalance in triglyceride and glycogen storage in the liver, muscle, heart, kidney, and adipose tissue. Meanwhile, rats treated orally with a No-observable-adverse-effect level (NOAEL) dose of metformin (200 mg/kg/day) showed mild improvement on serum lipids, but not on glucose tolerance; in tissues, glycogen storage was improved, but lipid storage was ineffective. In conclusion, metformin as a first-line pharmacological therapy must take into consideration the origin and duration of metabolic disruption, because in this work the NOAEL dose of metformin (200 mg/kg/day) showed a limited efficiency in the metabolic disruption caused by chronic Cd exposure.

Indexed as

cadmium toxicitymetabolic disruptormetabolic syndromemetformin

Identifiers

PMID30201894
PMCPMC6161094
OpenAlexW2890405915

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.